Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Clay Thorp sold 35,000 shares of Clearside Biomedical stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $8.57, for a total value of $299,950.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Clay Thorp also recently made the following trade(s):

  • On Thursday, September 14th, Clay Thorp sold 6,000 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.52, for a total value of $45,120.00.
  • On Wednesday, September 13th, Clay Thorp sold 8,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.49, for a total value of $63,665.00.
  • On Friday, September 15th, Clay Thorp sold 24,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.52, for a total value of $184,240.00.
  • On Tuesday, August 8th, Clay Thorp sold 5,000 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.98, for a total value of $39,900.00.
  • On Monday, August 7th, Clay Thorp sold 4,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $8.02, for a total value of $36,090.00.
  • On Wednesday, August 9th, Clay Thorp sold 24,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.57, for a total value of $185,465.00.

Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) traded up 1.19% during trading on Thursday, reaching $8.48. The company’s stock had a trading volume of 145,763 shares. Clearside Biomedical, Inc. has a 12-month low of $6.50 and a 12-month high of $25.08. The stock’s market capitalization is $214.85 million. The firm’s 50-day moving average is $8.13 and its 200-day moving average is $8.13.

Clearside Biomedical (NASDAQ:CLSD) last announced its quarterly earnings data on Wednesday, August 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.13). Clearside Biomedical had a negative return on equity of 65.78% and a negative net margin of 27,225.52%. The firm had revenue of $0.13 million during the quarter. Equities analysts expect that Clearside Biomedical, Inc. will post ($2.10) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Clearside Biomedical, Inc. (CLSD) Director Clay Thorp Sells 35,000 Shares” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/10/05/clearside-biomedical-inc-clsd-director-clay-thorp-sells-35000-shares.html.

Several large investors have recently made changes to their positions in CLSD. Nationwide Fund Advisors raised its stake in shares of Clearside Biomedical by 118.3% in the second quarter. Nationwide Fund Advisors now owns 11,703 shares of the company’s stock worth $107,000 after purchasing an additional 6,343 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of Clearside Biomedical in the second quarter worth about $117,000. Parametric Portfolio Associates LLC purchased a new position in shares of Clearside Biomedical in the second quarter worth about $122,000. Wells Fargo & Company MN raised its stake in shares of Clearside Biomedical by 325.0% in the first quarter. Wells Fargo & Company MN now owns 16,739 shares of the company’s stock worth $133,000 after purchasing an additional 12,800 shares during the last quarter. Finally, ProShare Advisors LLC raised its stake in shares of Clearside Biomedical by 4.0% in the second quarter. ProShare Advisors LLC now owns 14,814 shares of the company’s stock worth $135,000 after purchasing an additional 563 shares during the last quarter. Hedge funds and other institutional investors own 52.45% of the company’s stock.

A number of equities analysts have weighed in on CLSD shares. Cowen and Company reissued a “buy” rating on shares of Clearside Biomedical in a research report on Thursday, June 8th. ValuEngine raised Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Zacks Investment Research raised Clearside Biomedical from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a research report on Tuesday, July 11th. Finally, TheStreet lowered Clearside Biomedical from a “c-” rating to a “d” rating in a research report on Friday, August 11th. Two investment analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $19.00.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

Insider Buying and Selling by Quarter for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.